Revolution Medicines priced a $2 billion concurrent stock-and-debt offering, described as among the largest follow-on raises in biotech history, shortly after reporting top-line Phase 3 results for daraxonrasib in metastatic pancreatic cancer. The financing adds liquidity at a moment when the company is working toward a potential regulatory submission. Reporting also tied the funding surge to broader risk-on behavior in biotech, as investors rewarded high-conviction clinical data. The offering size suggests continued appetite for oncology assets with clear Phase 3 readouts. The deal structure and timing place Revolution Medicines as a bellwether for how clinical winners are capitalized ahead of FDA review windows.